NCEL
What one share of NewcelX holds
Pharmaceutical Preparations
NewcelX is a clinical-stage pharmaceutical company focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of hESCs into functional cells.
NewcelX’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | $2.16 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.72 |
| Cash and investments | $0.46 |
| Book value | $1.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$32.99 | — | −$17.52 | — | −$56.50 |
| 2019 | — | −$31.85 | — | −$1.11 | — | −$35.47 |
| 2020 | — | −$16.45 | — | −$4.19 | — | −$51.63 |
| 2021 | — | −$40.15 | $0.13 | −$50.33 | — | $1.34 |
| 2022 | — | −$33.52 | — | −$28.21 | — | $0.14 |
| 2023 | — | $1.13 | $0.00 | −$1.17 | — | — |
| 2024 | — | $2.43 | $0.00 | −$0.36 | — | −$2.70 |
| 2025 | — | $2.16 | $0.00 | −$0.72 | — | $1.51 |